cash flow reconciliationreview2025-12-31
Operating, investing and financing flows differ from the reported change in cash by 46000000, beyond tolerance 40160000.00.
Revenue
$24.95B
Fiscal year ended 2025-12-31Operating income
$4.63B
Fiscal year ended 2025-12-31Free cash flow
$1.40B
Fiscal year ended 2025-12-313M CO (MMM) reported revenue of $24.95B and net income of $3.25B for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from 3M CO’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.
Income
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $24.95B | $24.58B | $24.61B | $26.16B | $35.36B | $32.18B | $32.14B | $32.76B | $31.66B | $30.11B |
| Cost of revenue | $14.99B | $14.45B | $14.98B | $15.85B | $18.80B | $16.60B | $17.14B | $16.68B | $16.06B | $15.12B |
| Gross profit | $9.96B | $10.13B | $9.63B | $10.31B | $16.56B | $15.58B | $15.00B | $16.08B | $15.60B | $14.99B |
| Operating income | $4.63B | $4.82B | -$10.69B | $4.37B | $7.37B | $7.16B | $6.17B | $7.21B | $7.69B | $7.03B |
| Net income | $3.25B | $4.17B | -$7.00B | $5.78B | $5.92B | $5.45B | $4.52B | $5.35B | $4.86B | $5.05B |
| Research & development | Unavailable | $700.00M | $700.00M | $800.00M | $1.20B | $1.10B | $1.25B | $1.25B | $1.35B | $1.25B |
| Weighted-average diluted shares | shares 541.30M | shares 552.40M | shares 553.90M | shares 567.60M | shares 585.30M | shares 582.20M | shares 585.10M | shares 602.00M | shares 612.70M | shares 618.70M |
| Pretax income | $4.21B | $4.82B | -$11.27B | $4.20B | $7.20B | $6.80B | $5.64B | $7.00B | $7.55B | $7.05B |
| Income tax expense | $1.00B | $804.00M | -$2.87B | $188.00M | $1.28B | $1.34B | $1.11B | $1.64B | $2.68B | $2.00B |
| Diluted EPS | $6.00 | $7.55 | $-12.63 | $10.18 | $10.12 | $9.36 | $7.72 | $8.89 | $7.93 | $8.16 |
| Selling, general & administrative | $4.00B | $4.22B | $19.20B | $7.23B | $7.20B | $6.93B | $7.03B | $7.60B | $6.63B | $6.31B |
| General & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | $2.40B |
| Total assets | $37.73B | $39.87B | $50.58B | $46.46B | $47.07B | $47.34B | $44.66B | $36.50B | $37.99B | $32.91B |
| Current assets | $16.39B | $15.88B | $16.38B | $14.69B | $15.40B | $14.98B | $12.97B | $13.71B | $14.28B | $11.73B |
| Total liabilities | $32.99B | $35.97B | $45.71B | $31.68B | $31.96B | $34.41B | $34.53B | $26.65B | $26.36B | $22.56B |
| Current liabilities | $9.60B | $11.26B | $15.30B | $9.52B | $9.04B | $7.95B | $9.22B | $7.24B | $7.69B | $6.22B |
| Total equity incl. NCI | $4.75B | $3.89B | $4.87B | $14.77B | $15.12B | $12.93B | $10.13B | $9.85B | $11.62B | $10.34B |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $3.66B | $3.70B | $3.94B | $5.37B | $4.98B | $4.24B | $4.13B | $4.37B | $4.03B | $3.38B |
| Accounts receivable | $3.53B | $3.19B | $3.60B | $4.53B | $4.66B | $4.70B | $4.79B | $5.02B | $4.91B | $4.39B |
| Goodwill | $6.42B | $6.28B | $6.38B | $6.34B | $13.49B | $13.80B | $13.44B | $10.05B | $10.51B | $9.17B |
| Long-term debt | $10.93B | $11.12B | $13.09B | $14.00B | $16.06B | $17.99B | $17.52B | $13.41B | $12.10B | $10.68B |
| Accounts payable | $2.70B | $2.66B | $2.78B | $3.18B | $2.99B | $2.56B | $2.23B | $2.27B | $1.94B | $1.80B |
Cash flow
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $2.31B | $1.82B | $6.68B | $5.59B | $7.45B | $8.11B | $7.07B | $6.44B | $6.24B | $6.66B |
| Capital expenditures | $910.00M | $1.18B | $1.62B | $1.75B | $1.60B | $1.50B | $1.70B | $1.58B | $1.37B | $1.42B |
| Investing cash flow | $1.35B | -$3.21B | -$1.21B | -$1.05B | -$1.32B | -$580.00M | -$6.44B | $222.00M | -$3.09B | -$1.40B |
| Financing cash flow | -$4.02B | $1.10B | -$3.15B | -$5.35B | -$6.14B | -$5.30B | -$1.12B | -$6.70B | -$2.66B | -$4.63B |
| Net change in cash | -$365.00M | -$333.00M | $2.28B | -$909.00M | -$70.00M | $2.28B | -$500.00M | -$200.00M | $655.00M | $600.00M |
| Stock-based compensation | $225.00M | $289.00M | $274.00M | $263.00M | $274.00M | $262.00M | $278.00M | $302.00M | $324.00M | $298.00M |
| Common dividends paid | $1.56B | $1.98B | $3.31B | $3.37B | $3.42B | $3.39B | $3.32B | $3.19B | $2.80B | $2.68B |
| Common share repurchases | $3.25B | $1.80B | $33.00M | $1.46B | $2.20B | $368.00M | $1.41B | $4.87B | $2.07B | $3.75B |
| Depreciation & amortization | $1.31B | $1.36B | $1.99B | $1.83B | $1.92B | $1.91B | $1.59B | $1.49B | $1.54B | $1.47B |
Derived
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | $1.40B | $638.00M | $5.06B | $3.84B | $5.85B | $6.61B | $5.37B | $4.86B | $4.87B | $5.24B |
| Gross margin | 39.9% | 41.2% | 39.1% | 39.4% | 46.8% | 48.4% | 46.7% | 49.1% | 49.3% | 49.8% |
| Operating margin | 18.6% | 19.6% | -43.4% | 16.7% | 20.8% | 22.3% | 19.2% | 22.0% | 24.3% | 23.3% |
| FCF margin | 5.6% | 2.6% | 20.6% | 14.7% | 16.5% | 20.5% | 16.7% | 14.8% | 15.4% | 17.4% |
| SBC / revenue | 0.9% | 1.2% | 1.1% | 1.0% | 0.8% | 0.8% | 0.9% | 0.9% | 1.0% | 1.0% |
| Current ratio | 1.71x | 1.41x | 1.07x | 1.54x | 1.70x | 1.89x | 1.41x | 1.89x | 1.86x | 1.89x |
| Revenue YoY growth | 1.5% | -0.1% | -5.9% | -26.0% | 9.9% | 0.1% | -1.9% | 3.5% | 5.1% | Unavailable |
| Net margin | 13.0% | 17.0% | -28.4% | 22.1% | 16.7% | 16.9% | 14.1% | 16.3% | 15.3% | 16.8% |
| R&D / revenue | Unavailable | Unavailable | Unavailable | 3.1% | 3.4% | 3.4% | 3.9% | 3.8% | 4.3% | 4.1% |
| CapEx / revenue | 3.6% | 4.8% | 6.6% | 6.7% | 4.5% | 4.7% | 5.3% | 4.8% | 4.3% | 4.7% |
| Long-term debt / equity | 2.30x | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | 23.8% | 16.7% | Unavailable | 4.5% | 17.8% | 19.7% | 19.7% | 23.4% | 35.5% | 28.3% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open MMM in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-07-21View SEC filing
10-Q · Filed 2026-04-21View SEC filing
10-K · Filed 2026-02-03View SEC filing
10-Q · Filed 2025-10-21View SEC filing
10-Q · Filed 2025-07-18View SEC filing
10-Q · Filed 2025-04-22View SEC filing
Reconciliation checks needing review
1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.